Loading organizations...
Key people at Armistice Capital.
Armistice Capital was founded in 2015 by Steven Boyd (Founder & Managing Partner).
Armistice Capital operates as a global, long/short, value-oriented, and event-driven hedge fund, constructing portfolios primarily within the health care and consumer sectors. The firm employs rigorous investment methodology, identifying mispriced securities and capitalizing on corporate events. This strategy integrates in-depth fundamental research with opportunistic tactical maneuvers.
The firm was established in 2012 by Founder and Managing Partner Steven J. Boyd. Boyd's pedigree includes experience as a Senior Research Analyst at Senator Investment Group and earlier as a McKinsey consultant. His insight centered on generating alpha by combining deep sector-specific analysis with a flexible long/short, event-driven approach in less efficiently priced market segments.
Armistice Capital primarily serves institutional and sophisticated high-net-worth investors. The company’s vision is to deliver superior risk-adjusted returns to its partners through a disciplined value and event-driven investment philosophy. It focuses on uncovering overlooked opportunities and navigating market dynamics to foster long-term wealth creation.
Armistice Capital was founded in 2015 by Steven Boyd (Founder & Managing Partner).
Key people at Armistice Capital.
Armistice Capital has 1 tracked investment across 1 company. The latest tracked deal is $285.1M Other Equity in COMPASS Pathways in August 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 17, 2023 | COMPASS Pathways | $285.1M Other Equity | Aisling Capital, TCGX | Laurion Capital Management, Logos Capital, Paradigm BioCapital, PFM Health Sciences, RA Capital Management, Soleus Capital, Surveyor Capital, Vivo Capital |